antibody levels during convalescence in COVID-19 survivors with lymphoma, compared to other hematologic diseases (HemD) and healthy controls (Ctrls). Methods: Seventeen pts with non-Hodgkin lymphoma (NHL) [follicular (FL): 9; diffuse large B-cell (DLBCL): 8] surviving the acute phase of virologic-proven COVID-19 were evaluated at 3 timepoints (TP) after nasal swab negativity: +1 (TP1), +3 (TP3), and +6 (TP6) months; 28 pts affected by HemD (10 multiple myeloma, 8 chronic lymphoproliferative disorders, 10 myelodysplastic/chronic myeloproliferative syndromes) and 17 Ctrls were also evaluated at the same TP. Antibody

No abstract